Atlas Trials

Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma

Clinical trial NCT02405078 · COMPLETED

Trial details

NCT number
NCT02405078
Sponsor
M.D. Anderson Cancer Center
Status
COMPLETED
Phase
Early Phase 1
Study type
INTERVENTIONAL
Recurrent Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
Start date
2015-10-13
Primary completion
2022-10-03
Enrollment
35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.